Chart from Tracxn Industry Report on DiagnosticsNucleic acid-based assays and high throughput assays formed large upcoming sectors that drew most investments as total funding fell by 18% from the previous year in 2016 in the diagnostics space.

Chart from Tracxn Industry Report on DiagnosticsRound count soared only for seed (22%) as it dipped for both early and late with the fall being most pronounced for late (35%).

Chart from Tracxn Industry Report on DiagnosticsBy stage, funding dollars fell by 42% only for late as it soared for seed and early by 24% and 36% respectively.

Chart from Tarcxn Industry Report on DiagnosticsAverage ticket size climbed across the board-seed by 11%, Series A by 20% and Series B by 19%. Grail Bio’s Series B round of $900M and Guardant Health’s Series E round of $360M are top investments made in this space till date.

Chart from Tracxn Industry Report on DiagnosticsBy stage of entry, Y Combinator emerged as the top investor for seed, High-tech Grunderfonds for Series A, Sequoia Capital for Series B and Mohr Davidow Ventures for later stage.

16 companies have taken the public route in the last three years as 16 acquisitions have taken place in this sector till date.

Molecular Diagnostics with investments worth $4.8B has historically been the most funded business model followed closely by point-of-care diagnostics ($4.2B). Dollars to the tune of $3.5B have been invested in this sector between 2016-17.

Note: You can download the part view of the report here. The full version of this report is available for our paid subscribers. Should you want to access the complete report and explore the Tracxn platform, drop us a note on bd@tracxn.com

Download the Tracxn Industry Report on Diagnostics

Download Tracxn Industry Report on Diagnostics

Leave a Reply